FDA Approves Dexcom Stelo CGM for Pediatric Use

Key Facts

1The FDA cleared Dexcom's OTC Stelo CGM for children ages 2 and older, expanding access to real-time glucose monitoring.

In a move that strengthens the company's leadership in the home healthcare market, Dexcom announced that the U.S. Food and Drug Administration (FDA) has cleared its Stelo device for expanded use. This approval allows the over-the-counter (OTC) continuous glucose monitor (CGM) to be used by children as young as 2 years old. The expansion aims to provide real-time glucose monitoring options to a broader pediatric demographic without requiring a prescription.

This regulatory milestone comes amid intensifying competition in the CGM sector, as Dexcom seeks to maintain its edge over rivals like Abbott's FreeStyle Libre system. Per market data, DXCM shares closed at $75.37 on June 12, 2026, navigating a daily range between $73.53 and $76.25. Analysts suggest that entering the pediatric market provides a strategic growth catalyst by tapping into a segment with high demand for accessible health technology.

Investors should watch the current support levels for DXCM at $73.53 based on the June 12, 2026 close. Looking ahead, U.S. inflation data (CPI) released on June 10, 2026, remains a broader macro catalyst for growth-oriented healthcare stocks. The primary focus for the upcoming quarter will be the adoption rate among pediatric users and its subsequent impact on Dexcom's revenue streams.